

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Raily Aesthetic Medicine International Holdings Limited**

**瑞麗醫美國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2135)**

### **VOLUNTARY ANNOUNCEMENT IN RELATION TO ACQUISITION OF 25% EQUITY INTEREST OF THE TARGET**

This announcement is made by Raily Aesthetic Medicine International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest information in relation to the business development of the Company.

#### **THE ACQUISITION**

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 12 July 2021, Shenzhen Ruiquan Management Consulting Co., Ltd. (“**Shenzhen Ruiquan**”), an indirect wholly owned subsidiary of the Company, entered into a capital increase agreement with, among others, 比奧瑞思醫美（北京）商貿有限公司 (Biotrisse Aesthetic Medicine (Beijing) Trading Co., Ltd\*) (the “**Target**”). Pursuant to the capital increase agreement, Shenzhen Ruiquan agrees to contribute RMB3,500,000 to the capital of the Target and to acquire 25% equity interests in the Target (the “**Acquisition**”).

To the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries, the Target is a third party independent of the Company and its connected persons (as defined under The Rules of Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Completion of the capital increase agreement is conditional upon satisfaction of the conditions precedent contained in the capital increase agreement.

## **INFORMATION OF THE TARGET**

The Target is a company incorporated in the PRC with limited liability and is principally engaged in the sales of cosmetics, daily necessities, medical devices, and the provision of software development, corporate planning, exhibition event, conference, technology promotion, and import and export agent services.

## **REASONS FOR AND BENEFITS OF THE ACQUISITION**

The aesthetic medical services of the Group principally include (i) aesthetic surgery services, comprising aesthetic surgical procedures performed on various parts of the face or body; (ii) minimally-invasive aesthetic services, primarily comprising aesthetic injection procedures; and (iii) aesthetic dermatology services, primarily comprising various aesthetic energy-based procedures.

Other than focusing on its existing businesses, the Group plans to pursue acquisition and investment opportunities for vertical expansion of the supply chain of the aesthetic medical services industry, i.e. investing in or entering into business alliance with upstream suppliers of aesthetic medical consumables or equipment in order to have better costs and quality control of our supplies and broaden our source of revenue.

The Board is of the view that the terms of the Acquisition are fair, reasonable and in the best interests of the Company and its shareholders as a whole.

## **LISTING RULES IMPLICATIONS**

As all of the relevant applicable percentage ratios under Rule 14.07 of the Listing Rules in respect of the Acquisition are less than 5%, the Acquisition does not constitute a notifiable transaction for the Company under Chapter 14 of the Listing Rules. This announcement is being made by the Company on a voluntary basis.

By order of the Board  
**Raily Aesthetic Medicine International Holdings Limited**  
**Mr. Fu Haishu**  
*Chairman*

Hong Kong, 12 July 2021

*As at the date of this announcement, the Board comprises Mr. Fu Haishu, Mr. Yu Kai and Mr. Song Jianliang as executive Directors; Mr. Xie Lijun and Ms. Fan Qirui as non-executive Directors; and Mr. Cao Dequan, Ms. Yang Xiaofen and Mr. Liu Teng as independent non-executive Directors.*

\* *For identification purposes only*